Subscribe to RSS
DOI: 10.1055/s-0038-1651111
Fibrinogen Vicenza and Genova II: Two New Cases of Congenital Dysfibrinogenemia with Isolated Defect of Fibrin Monomer Polymerization and Inhibitory Activity on Normal Coagulation
Publication History
Received 08 April 1986
Accepted after revision 30 January 1987
Publication Date:
06 July 2018 (online)
Summary
Two new cases of congenital dysfibrinogenemia are presented in which defective fibrin monomer polymerization and inhibitory activity on normal coagulation were observed. They have been tentatively called fibrinogen Vicenza and Genova II. The first was discovered in a family with mild bleeding diathesis, the second in an asymptomatic family. In almost all reported cases of fibrinogens with defective fibrin monomer polymerization, additional functional or structural defects have been detected. In our cases, on the contrary, detailed investigations failed to show any other abnormality. Fibrinogen Genova II is apparently identical to fibrinogen Baltimore IV, whereas fibrinogen Vicenza is similar to fibrinogen Tloyes and Genovz I, but also exerts an evident inhibitory activity on normal coagulation and differs from fibrinogen Genova II and Baltimore IV showing a different kinetic pattern of fibrin monomer polymerization.
-
References
- 1 Bithell TC. Hereditary dysfibrinogenemia. Clin Chem 1985; 31: 509-516
- 2 Gralnick HR. Congenital disorders of fibrinogen. In “Hematology”. Williams JW, Beutler E, Erslev AJ, Lichtmann MA. (eds.). pp.. 1399-1410 McGraw Hill; New York: 1983
- 3 Rodeghiero F, Mannucci PM, Viganò S, Barbui T, Gugliotta G, Cortellaro M, Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63: 965-969
- 4 Rodeghiero F, Barbui T, Battista R, Chisesi T, Rigoni G, Dini E. Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukemia. Thromb Haemostas 1980; 43: 6-9
- 5 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
- 6 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-254
- 7 Schulz FH. Eine einfache Bewertungsmethode von Leberparenchymschaden (volumetrische Fibrinbestimmung). Acta Hepato splen 1955; 3: 306-310
- 8 Jakobsen E, Kierulf P. A modified β-alanine precipitation procedure to prepare fibrinogen free of antithrombin III and plasminogen. Thromb Res 1973; 3: 145-159
- 9 Warren L. The thiobarbituric acid assay of sialic acid. J Biol Chem 1959; 234: 1971-1975
- 10 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
- 11 Weber L, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
- 12 Haverkate F, Koopman J, Kluft C, D’Angelo A, Cattaneo M, Mannucci PM. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Thromb Haemostas 1986; 55: 131-135
- 13 Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa). J Lab Clin Med 1975; 85: 574-579
- 14 Dardik BN, Shainoff JR. Crosslinking of monomeric fibrin by factor XIIIa. Thromb Haemost 1979; 42: 864-872
- 15 Budzynski AZ, Marder VJ. Plasmic degradation of fibrinogen Paris I. J Lab Clin Med 1976; 88: 817-825
- 16 Mosesson MW, Natale PD, Amrani DL, Sherman LA, Joist JH, Krause WH. Comparison of plasmic hydrolysis of normal fibrinogen and fibrinogen Giessen I. Thromb Res 1978; 12: 693-696
- 17 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res 1977; 10: 803-812
- 18 Gralnick HR, Coller BS, Fratantoni JC, Martinez J. Fibrinogen Bethesda III: a hypodysfibrinogenemia. Blood 1979; 53: 28-46
- 19 Carrell N, Gabriel DA, Blatt PM, Carr ME, McDonagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 1983; 62: 439-447
- 20 Hassan HJ, Orlando M, Tonini GP, Casalbore P, Sarti A, Boeri E, Giacchino R, Tentori L, Mori GP. An abnormal inherited fibrinogen (Fibrinogen Genova) with delayed fibrin aggregation. Scand J Haematol 1982; 29: 287-294
- 21 Ebert RF, Bell WR. Fibrinogen Baltimore IV: congenital dysfibrinogenemia with delayed fibrin monomer polymerization. Thromb Res 1985; 38: 121-128
- 22 Vila V, Reganon E, Fernandez-Pavon A, Aznar J. Dysfibrinogenemia associated with a defect in the aggregation of the fibrin monomers (Almeria I fibrinogen). A preliminary study. Scand J Haematol 1984; 33: 460-465
- 23 Soria J, Soria C, Hedner U, Nilsson IM, Bergqvist D, Samama M. Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenemia (fibrinogen Malmö). Brit J Haematol 1985; 61: 727-738